Laura Torrecillas

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Aňa Lluch, Carlos H. Barrios, Laura Torrecillas et al. · Journal of Clinical Oncology · 2019 · 153 citations · Full text

Medicine, Oncology, Pharmacology +17

Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial

Laura Torrecillas, Sylvia A. Reyes, María Teresa Ramírez et al. · Journal of Clinical Oncology · 2006 · 52 citations

Medicine, Oncology, Pharmacology +17

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

Karama Asleh, Aňa Lluch, Angela Goytain et al. · Clinical Cancer Research · 2022 · 28 citations · Full text

Medicine, Oncology, Pharmacology +17

Communication of the Cancer Diagnosis to Mexican Patients

Laura Torrecillas · Annals of the New York Academy of Sciences · 1997 · 20 citations

Public Health, Oncology, Health Communication +12

Abstract P5-10-15: First Safety Data from a Randomised Phase III (CIBOMA 2004- 01/GEICAM 2003-11) Trial Assessing Adjuvant Capecitabine Maintenance Therapy after Standard Chemotherapy for Triple-Negative Early Breast Cancer

Aňa Lluch, Henry Gómez, Manuel Ruíz‐Borrego et al. · Cancer Research · 2010 · 10 citations

Medicine, Oncology, Pharmacology +17